Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
27 August 2024 - 2:00PM
Business Wire
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the
“Company”), an experienced and innovative biotechnology company
committed to transforming people’s lives by silencing diseases
through precision engineered medicines, today announced that
management will present company overviews at the following
conferences:
- Morgan Stanley Global Healthcare Conference on Thursday,
September 5, 2024 at 5:35pm ET
- HC Wainwright Global Investment Conference on Tuesday,
September 10, 2024 at 11:30am ET
- Cantor Global Healthcare Conference on Tuesday, September 17,
2024 at 10:20am ET
- Chardan Genetic Medicines Conference on Monday, September 30,
2024 at 9:00am ET
A live audio webcast of each presentation will be available on
the Company’s website at www.silence-therapeutics.com. A replay
will be available on the Silence website within 48 hours after of
each event.
About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, to inhibit the expression of specific target genes thought to
play a role in the pathology of diseases with significant unmet
need. Silence's proprietary mRNAi GOLD™ platform can be used to
create siRNAs (short interfering RNAs) that precisely target and
silence disease-associated genes in the liver, which represents a
substantial opportunity. Silence's wholly owned product candidates
include zerlasiran designed to address the high and prevalent unmet
medical need in reducing cardiovascular risk in people born with
elevated levels of lipoprotein(a) and divesiran designed to address
hematological diseases, including polycythemia vera. Silence also
maintains ongoing research and development collaborations with
AstraZeneca and Hansoh Pharma, among others. For more information,
please visit https://www.silence-therapeutics.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240827212540/en/
Silence Therapeutics plc Gem Hopkins, VP, Head of IR and
Corporate Communications ir@silence-therapeutics.com Tel: +1 (646)
637-3208
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Silence Therapeutics (NASDAQ:SLN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024